



PRESS RELEASE

AMOEBA BIOCONTROL SOLUTIONS TESTED BY EVERGREEN GARDEN CARE FOR HOME GARDEN APPLICATIONS

Chassieu (France), april 14 2020 - AMOEBEA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Material Transfer Agreement (MTA) with the leading garden care company in Europe and Oceania, EVERGREEN GARDEN CARE. The purpose of this partnership is to evaluate the performance of Amoéba's biocontrol products which, if successful, could lead to the development of a new range of products for hobby gardeners.

Trials on new crops and new types of plants

Known for its consumer brands (KB, Substral, Fertilizer...), available in specialist garden centers, DIY stores and online retailers, EVERGREEN GARDEN CARE wants to test Amoéba's *Willaertia magna C2c Maky* amoeba lysate on different diseases found in gardens and vegetable gardens.

Trials will include the following crops and plants:

- Potatoes (for late blight);
- Roses and other ornamentals (for rust and black spot).

Europe as a testing ground to meet the demands of individuals.

Through the program launched by EVERGREEN GARDEN CARE, the Amoéba lysate will be tested in France, the United Kingdom, the Netherlands and Poland.

In France, the entry into force of the Labbé law compels local authorities (since 1 January 2017) and private individuals (since 1 January 2019) to no longer use or hold plant protection products, except for biocontrol products, which are low-risk and authorized for organic agriculture. Amoéba's future products, developed from the amoeba lysate, could be particularly suited to this market in response to amateur gardeners' expectations and requirements for natural treatment products with no environmental impact.

Amoéba and EVERGREEN GARDEN CARE are thus embarking on a targeted research phase that could promote the commercial development of Amoéba's biocontrol solutions for the general public.

«This new partnership illustrates the will to respond to the general public new demands for high-performance and environmentally friendly solutions. Resulting from 10 years of research and development, 100% organic, non-genetically modified and targeting fungi, our Willaertia magna C2c Maky amoeba lysate is an alternative response to the "all chemical" in our gardens and vegetable gardens. These trials will make it possible to develop new formulations thus broadening the spectrum



of applications and, if they are conclusive, to offer products to individuals that have already been tested on field crops, » explains Fabrice Plasson, Chairman and CEO of Amoéba

Amoéba points out that the company is still in the testing phase for its biocide and biocontrol applications and does not currently market any products.

About EVERGREEN GARDEN CARE

Evergreen Garden Care is the leading garden care company outside North America, producing high quality garden care products designed to help people create their own green oasis amid the rush of modern life. We believe in the beauty of a green space - or oasis - whether it's a garden, balcony or potted plants indoors, and we want to inspire anyone, anywhere, to make it easier to create and maintain their own.

Founded in 2017 through the exclusive acquisition of the international operations of Scotts Miracle-Gro, Evergreen Garden Care is a team of 800 passionate people whose primary mission is to help all levels gardeners to maintain their lawns, grow fruits and vegetables to make their own green oasis as beautiful as possible. With market-leading brands such as Miracle-Gro, Fertilizer, Substral and Pokon in all the markets where we operate, we offer a full range of products to gardeners in the UK, France, Belgium, the Netherlands, Germany, Austria, Poland, the Nordic countries, Australia and New Zealand. Our aim is to develop the best known brands and launch the most exciting and relevant innovations for the consumer as we develop our new company.



About AMOÉBA :

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn ⁽²⁾ and on the biocontrol market for plant protection estimated globally at €1.6Bn ⁽⁴⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIFrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Investors and Media Relations

Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90

gregory.bosson@calyptus.net



Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 25, 2019 under number D19-0383 and the prospectus approved by the AMF on January 16, 2020 under number 20-011 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.